المؤلفون: A. V. Nikitina, F. V. Gorkavenko, Y. S. Saybel, M. V. Avxentyeva, M. S. Sura, D. V. Fedyaev

المصدر: Фармакоэкономика, Vol 12, Iss 4, Pp 300-308 (2020)

مصطلحات موضوعية: antitumor drug, reference drug, generic drug, biosimilar, oncology, cost optimization, Therapeutics. Pharmacology, RM1-950, Economics as a science, HB71-74

وصف الملف: electronic resource

Relation: https://www.pharmacoeconomics.ru/jour/article/view/320; https://doaj.org/toc/2070-4909; https://doaj.org/toc/2070-4933

URL الوصول: https://doaj.org/article/6826a6398ad646508ffcc694d20556c8

المؤلفون: F. V. Gorkavenko, D. V. Fedyaev, M. S. Sura, A. V. Nikitina, M. Avxentyeva, Y. S. Saybel

المصدر: Фармакоэкономика, Vol 12, Iss 4, Pp 300-308 (2020)

مصطلحات موضوعية: Drug, Drug supply, media_common.quotation_subject, Population, RM1-950, reference drug, 03 medical and health sciences, 0302 clinical medicine, Generic drug, 030212 general & internal medicine, Baseline (configuration management), education, HB71-74, media_common, Pharmacology, Consumption (economics), education.field_of_study, Actuarial science, Health Policy, Public Health, Environmental and Occupational Health, Biosimilar, antitumor drug, Economics as a science, 030220 oncology & carcinogenesis, oncology, Russian federation, generic drug, Business, Therapeutics. Pharmacology, biosimilar, cost optimization

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da932f989b27a2c50f30ccc073964bd6
https://www.pharmacoeconomics.ru/jour/article/view/320